PulseAugur
EN
LIVE 06:08:26
ENTITY T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy

PulseAugur coverage of T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy — every cluster mentioning T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy across labs, papers, and developer communities, ranked by signal.

Show in brief
Total · 30d
1
1 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
TOPICS
SENTIMENT · 30D

1 day(s) with sentiment data

RECENT · PAGE 1/1 · 1 TOTAL
  1. RESEARCH · CL_256637 ·

    GSK licenses Chinese cancer drug for up to $750M

    GSK has agreed to acquire global rights to a novel T-cell engager cancer drug from Chinese firm Chimagen Biosciences. The deal, potentially worth up to US$750 million, focuses on a treatment for multiple myeloma that ai…